Dendreon Corporation (NASDAQ:DNDN) Selling Off After Earnings Reports (Recap)

Experts Expectations vs Actual:

The company reported an adjusted net loss of 59 cents per share. The company beat the expert’s estimate of a loss of 65 cents per share. Experts were expecting revenue of $81.2 million.

Dendreon Corporation vs Industry Leaders:

The company is ranked 216^th among Biotechnology Company by return on equity which stands at -48.17 percent. The company maintains the 28^th highest market capitalization of $1.29 billion among its industry peers. The company is ranked 14^th among its competitors by long term growth rate.

1^st Quarter 2012 Financial Results:

Revenue:

Dendreon Corporation (NASDAQ:DNDN) reported the revenue of $82.07 million for the quarter ended March 31^st, 2012 as compared to revenue of $27 million for the same period last year.

Net Income 2012 vs Net Income 2011:

Dendreon Corporation (NASDAQ:DNDN) reported the net loss of $103.91 million or loss of $0.67 per share for the respective quarter as compared to net loss of $112.81 million or loss of $0.78 per share last year.

Balance Sheet:

The company’s total assets accumulate up to $941.96 million with highest proportion of current assets in its composition. The company maintains strong short term liquidity position as per its current ratio of 7.35 times. Its total liabilities stand at $662.43 million as compared to its total equity of $279.53 million.